Vaxcyte prices $500M equity offering and $500M convertible notes offering to fund VAX-31 program

Vaxcyte priced its concurrent public offerings of common stock, pre-funded warrants and convertible senior notes, raising $500M in equity and $500M in convertible notes to fund its VAX-31 program.

Detected & updated continuously · Source: Nebula